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Abstract
Background: Decision making regarding future fertility can be very difficult for fe-
male cancer patients. To support patients in decision making, fertility preservation de-
cision aids (DAs) are being developed. However, to make a well-informed decision, 
patients need personalized information tailored to their cancer type and treatment. 
Tailored cancer-specific DAs are not available yet.
Methods: Our DA was systematically developed by a multidisciplinary steering 
group (n = 21) in an iterative process of draft development, three rounds of alpha 
testing, and revisions. The drafts were based on current guidelines, literature, and 
patients' and professionals' needs.
Results: In total, 24 cancer-specific DAs were developed. In alpha testing, cancer 
survivors and professionals considered the DA very helpful in decision making, and 
scored an 8.5 (scale 1–10). In particular, the cancer-specific information and the tool 
for recognizing personal values were of great value. Revisions were made to increase 
readability, personalization, usability, and be more careful in giving any false hope.
Conclusions: A fertility preservation DA containing cancer-specific information is 
important in the daily care of female cancer patients and should be broadly available. 
Our final Dutch version is highly appraised, valid, and usable in decision making. 
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1 |  INTRODUCTION
Improved survival rates for cancer patients of reproductive 
age have increased the importance of addressing long-term 
side effects of cancer treatments.1 Potential loss of fertility 
due to the gonadotoxicity of cancer treatments is an import-
ant long-term side effect for female cancer survivors of repro-
ductive age.2 Therefore, guidelines recommend that the risk 
of infertility and fertility preservation (FP) options should be 
discussed before the start of the cancer treatment.3,4 Current 
FP options include cryopreservation of oocytes, embryos, 
and ovarian tissue, ovarian transposition, ovarian suppres-
sion, and fertility sparing surgery.
Patients want to be informed about the effects of can-
cer treatment on their fertility and the available FP options 
via written and/or digital information in order to make a 
well-informed decision.5,6 However, studies have shown that 
in current care not all patients are informed on these risks 
and options, and patients have reported unmet information 
needs.7-9 Even if information on fertility risks and options is 
provided, decision making regarding future fertility is very 
difficult and complex. The decision has to be made in a very 
short time frame in a period with great emotional distress in 
which patients and their partners focus on surviving cancer 
and not on their future fertility.6 In addition, not all FP op-
tions are appropriate for all patients. Dependent on patient's 
age, relationship status, cancer type, cancer treatment, prog-
nosis, and the amount of time before starting cancer treat-
ment, some preservation options are more appropriate than 
others. As a consequence, patients experience decisional 
conflict regarding this decision. Decisional conflict increases 
if patients did not obtain enough information on all FP op-
tions, and if patients did not feel supported during decision 
making.9-11 This suboptimal care in information provision 
and support increases concerns regarding fertility and long-
term regret, affecting female cancer patients' quality of life 
negatively.2,12,13
Therefore, it is important that female cancer patients are 
well informed and supported in their decision regarding 
FP. Providing a decision aid (DA) is a way to support pa-
tients in this complex decision-making process. DAs are de-
scribed as evidence-based tools designed to support patients 
in making choices among healthcare options. They provide 
evidence-based information on the options, associated bene-
fits, and harms, and help patients to recognize their personal 
values in the decision-making process. DAs increase patients' 
knowledge and decrease their decisional conflict compared 
to usual care.14
A recent study reviewed and evaluated nine FP DAs.15 
These DAs significantly increased FP knowledge and de-
creased decisional conflict. Furthermore, they were found to 
be helpful, contained relevant information, and patients re-
ported high levels of satisfaction with their use. Only three 
of these nine DAs are currently available for female cancer 
patients: one for breast cancer patients, and two not specific 
to any cancer type, in Portuguese and in German.16-18
However, DAs that personalize information based on can-
cer type and treatment are not available yet. Therefore, the 
aim of this study was to develop and test an online Dutch FP 
DA tailored to cancer type and associated cancer treatments 
and infertility risks for female cancer patients of reproductive 
age.
2 |  METHODS
2.1 | Development process
The FP DA was systematically developed in 2019/2020 
using the recommendations published by Coulter et al.19 
and in accordance with the international patient DA stand-
ards (IPDAS) criteria.20 The development process is shown 
in Figure 1 and was performed by a project group (N = 6) 
guided by a multidisciplinary steering group (N = 15) consist-
ing of healthcare professionals working in female oncofertil-
ity care throughout the Netherlands, female cancer survivors 
and patient advocates (affiliated with a patient association). 
They were recruited from the working group who developed 
the Dutch FP guideline in 2016.4 This study was approved 
by the Medical Ethical Committee of the Radboudumc 
(2018–4996), and all participants provided written consent 
to participate.
2.1.1 | Setting
In the Netherlands, cancer patients receive multidisci-
plinary oncological care and can be referred for special-
ized FP care by any medical specialist involved. At three 
Dutch hospitals, all FP options, including ovarian tissue 
After evaluating its effectiveness with newly diagnosed patients, the DA can be trans-
lated and adjusted according to (inter)national guidelines.
K E Y W O R D S
cancer, decision aid, fertility preservation, shared decision making, tailored information
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F I G U R E  1  Systematic development process of the fertility preservation decision aid
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cryopreservation, are performed. All legal residents of the 
Netherlands are obliged by law to have basic health in-
surance, which covers FP counseling and all FP options, 
meaning that patients have no financial reasons to refrain 
from it.
2.1.2 | Scope and purpose
The scope and purpose of the DA was defined by the project 
group. It should be part of the implementation of the national 
FP guideline. A meeting was held with the project and steer-
ing group to reach consensus on the scope, purpose, target 
audience, and moment of providing the DA.
2.1.3 | Content and format
Patients' needs and preferences—data collection
To explore patients' needs and preferences in a FP DA, in-
depth interviews were conducted with female cancer sur-
vivors who had FP counseling and made a decision on FP 
treatment in the past. They were recruited from an academic 
medical center. A topic list guided the interviews and sur-
vivors were asked for their opinion about: the content, the 
format, ways to personalize the DA, a value clarification ex-
ercise, how much time they want to spent on the DA, and the 
moment of providing the DA. The interviews were conducted 
by M.B. (researcher); took place at the academic medical 
center or by telephone, depending on patients' preferences; 
and lasted approximately 30 min. The number of interviews 
was determined by data saturation (the point at which no new 
information was mentioned).
Patients' needs and preferences—data analysis
All interviews were audio recorded, transcribed ver-
batim, and analyzed through grounded theory analysis 
using qualitative research software Atlas.ti (version 8.2, 
Berlin).21 Data were anonymized, and the transcripts were 
not returned to participants for comments or feedback. 
The coding process consisted of the following steps. Each 
step was performed independently by two researchers to 
increase reliability and validity. All interviews were read 
first. Second, both researchers selected and labeled phrases 
describing experiences or improvement suggestions, using 
open encoding (ie, using patients' own words). The de-
scriptive codes that showed resemblance were combined 
and redefined into specific subthemes. These subthemes 
were then merged into broader themes by using axial cod-
ing. The broader themes formed the conceptual model for 
patients' needs and preferences that was devised by using 
the grounded theory method. After each step, the results 
were compared, and any discrepancies were discussed until 
consensus was reached. In addition, each interview was an-
alyzed directly, so new topics could be added to the initial 
topic list.
Professionals' needs and preferences—data collection
As part of our previous study, 24 oncological health-
care providers and reproductive specialists were inter-
viewed about their barriers and improvement suggestions 
in female oncofertility care.6 They were recruited from 
the three Dutch expertise hospitals for female FP care 
(Radboudumc, LUMC, and ErasmusMC) and their af-
filiated hospitals (ca.20). All interviews were conducted 
by M.B., and depending on professional's preference, in-
terviews were conducted in person or via telephone, and 
lasted approximately 40 min. An interview guide was used 
to standardize the interview process, and the number of in-
terviews was determined by data saturation.
Professionals' needs and preferences—data analysis
Analysis of professionals' needs and preferences was 
part of our previous study and is described in our pub-
lished paper.6 In short, coding of the interviews was in-
dependently performed by two authors and was guided by 
Flottorp's framework.22
Content
Besides the interviews, a literature review was performed 
to provide information on current infertility risks and preg-
nancy chances of FP options. The following domains were 
important in FP decision making according to professionals' 
interviews and the literature review6: (1) infertility risks asso-
ciated with cancer treatment; (2) burden and risks of FP treat-
ment; (3) pregnancy chances associated with FP options; (4) 
consequences of the decision for future fertility; (5) patients' 
personal values in decision making. The content of these do-
mains was tailored according to patients' needs and prefer-
ences. The current national FP guideline formed the basis for 
the content of domain 1–4.4 For the fifth domain, important 
items to clarify patients' values in decision making were ex-
tracted from patients' interviews.
Format
An online, Web-based, format was chosen by the project and 
steering group to be able to provide a DA that is tailored to a 
patient's cancer type.
2.2 | Methods of alpha testing and revision
2.2.1 | Data collection
After an iterative process of reviewing and revising the con-
tent with the project and steering group, the first draft was 
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evaluated by an organization with experience in adjusting 
medical texts for low literacy patients (www.stich tingm 
akkel ijkle zen.nl). The second draft was evaluated with fe-
male cancer survivors who made a decision regarding FP 
in the past, and with patient advocates. They were recruited 
from an academic medical center and patient associations. 
All interviews were conducted by M.B., and the number of 
interviews was determined by data saturation. The first part 
of the interview was unstructured according to the think 
aloud method.23 The second part was semi-structured, and 
participants were asked about the content, layout, com-
prehensibility, usability, and acceptability of the DA.24-26 
Based on the received feedback, a third draft was devel-
oped and alpha-tested with professionals working in on-
cofertility care, as suggested by Coulter,19 recruited from 
the steering group. They were also invited for an interview, 
conducted by M.B., using the think aloud method,23 and 
were asked to fill in a questionnaire with questions about 
the content, clearness, and usefulness, and were asked to 
rate the DA.25,26 The number of interviews was, again, de-
termined by data saturation. Finally, a revised fourth draft 
was quantitatively evaluated with female cancer survivors 
and patient advocates using a questionnaire similar to the 
professionals' questionnaire. They were, again, recruited 
from an academic medical center and patient associations. 
In addition to the quantitative evaluation, the quality of the 
fourth draft was tested against the 64 IPDAS criteria.
2.2.2 | Data analysis
Again, all patients' and professionals' interviews were 
audio recorded, transcribed verbatim, and analyzed using 
qualitative research software Atlas.ti (version 8.2, Berlin). 
Patients' and professionals' data were anonymized and ana-
lyzed separately. The transcripts were not returned to par-
ticipants for comments or feedback. The coding process 
consisted of the following steps and was performed by two 
authors (M.B. and E.M.). All interviews were read first. 
Second, both authors selected and labeled phrases describ-
ing feedback and improvement suggestions per chapter of 
the decision aid, using open encoding (ie, using patients' 
own words). All feedback and improvement suggestions 
were listed and discussed in a face-to-face meeting with the 
project group. After reaching consensus with the project 
group on which suggestions should be incorporated in the 
new draft, all decision aids were revised and evaluated in 
the next round of alpha testing. Patients' and professionals' 
questionnaires were analyzed using SPSS (version 25.0 for 
Windows). Regarding the IPDAS criteria, all members of 
the project group evaluated the 64 IPDAS criteria indepen-
dently, where after consensus was reached in a face-to-face 
meeting.
3 |  RESULTS
3.1 | Development process
3.1.1 | Scope and purpose
The scope and purpose of the DA was twofold. The main 
scope was to support female cancer patients in their deci-
sion whether they want to undergo a FP treatment or not. 
Furthermore, the DA also supports patients in the decision 
which FP treatment they want to undergo. The steering group 
agreed that the DA should be provided before FP counseling 
with a reproductive gynecologist and is meant to be comple-
mentary to the counseling. Furthermore, the target audience 
was defined as female cancer patients of reproductive age 
(>18 years) who have to undergo a gonadotoxic cancer treat-
ment. No cancer types were excluded.
3.1.2 | Content and format
Patients' needs and preferences—results
Nine out of nineteen female cancer survivors participated in 
the in-depth interview about their needs and preferences in 
a FP DA. Their mean age was 32 years (SD 6,8 years), they 
were diagnosed with breast cancer (78%) or Hodgkin's lym-
phoma (22%), and all had undergone a FP treatment.
Regarding the content, all patients mentioned that the DA 
should be developed per cancer type, so they do not have to 
read information that is not applicable to them. Furthermore, 
the most important topics to provide were the consequences 
of cancer treatment for fertility and the live birth rate per FP 
treatment. Patients expressed a need to know their personal 
risk of infertility in order to make a decision, meaning that 
the risk of infertility should be provided per cancer treatment. 
The burden, risks, pros, and cons of each FP option should 
be extensively provided. In addition, some patients wanted to 
read about egg donation, adoption, foster care, and surrogacy 
and the steps to go through if you have a wish to conceive 
after surviving cancer, because patient information about 
these topics is lacking at this moment in the Netherlands.
Another topic in the interviews was the way the DA 
should be personalized. As stated before, all patients wanted 
a DA personalized to their cancer type. Regarding FP treat-
ments, patients wanted to read about the following options: 
“wait and see,” oocyte, embryo, and ovarian tissue cryopres-
ervation, even if one of those options was not applicable to 
them. They did not want to have the feeling that options were 
deliberately withheld from them. However, it should be very 
clear for whom the treatment is applicable.
All patients wanted to use the DA online and wanted to 
spent about 30 min on the DA. Most patients would use the 
DA before counseling with a reproductive gynecologist; 
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however, some patients mentioned they had been so over-
whelmed by the cancer diagnosis that they would use the DA 
after counseling.
Professionals' needs and preferences—results
In total, 24 out of 43 individual professionals agreed to par-
ticipate in the interviews about their barriers and improve-
ment suggestions in female oncofertility care. Regarding 
barriers in information provision, professionals mentioned 
that there was a lack of written and digital information for 
patients. Furthermore, professionals mentioned that patients 
had a need for FP information tailored to their personal situ-
ation to be able to make a decision.
Content and format
Based on patients' and professionals' needs and prefer-
ences, the project and steering group decided to develop 24 
cancer-specific DAs, one for each cancer type occurring in 
young females (Figure 2). Patients have access to one spe-
cific DA, that is, access to the DA specific to their cancer 
type. All DAs were divided into five chapters: Information; 
Comparison of options; Important items; Your preference 
and values; and Closure, and arranged in the same way and 
are comparable to each other. There is one exception, the 
DAs for gynecological cancers are really different from 
all other DAs, as the cancer treatment itself could already 
be a FP option. The first chapter “Information” begins 
with an introduction for whom the DA is applicable and 
the purpose. Thereafter, general information about cancer 
treatment and infertility is provided. In the next section, for 
each cancer type (ie, different in each DA) tailored infor-
mation about all possible cancer treatments that could be 
given for that specific cancer type is presented including 
their consequences for fertility and uterine function, if ap-
plicable. After reading about infertility risks, the decision 
is displayed, “wait and see” versus “FP treatment” includ-
ing all applicable treatments for that specific cancer type. 
In the next pages, extensive information about the follow-
ing topics is provided for all options; for whom the op-
tion is appropriate, explanation about treatment, live birth 
rate, safety, risks, pros, and cons. For example, for breast 
cancer patients, oocyte and embryo cryopreservation are 
presented as good and applicable options, and for leuke-
mia patients, these are presented as not so applicable, as 
there might be no time before starting cancer treatment. 
Furthermore, an image has been developed to explain 
each treatment. This chapter ends with information about 
the steps to go through when a patient has a wish to con-
ceive after surviving cancer, including alternative family 
building options. In chapter 2, patients can compare all FP 
options including “wait and see” in an interactive table. 
To personalize this table, patients can check and uncheck 
all options and all above-mentioned topics. In chapter 3, 
patients are asked to answer basic questions about cancer 
and fertility to check whether they understood the informa-
tion. In the fourth chapter, patients are asked to fill in a 
F I G U R E  2  Overview of the 24 developed cancer-specific decision aids
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value clarification exercise containing nine statements to 
recognize their personal values in decision making. In the 
final chapter, patients are asked to fill in three questions to 
clarify if they had gained enough knowledge, learned about 
their values in this decision, and if they were prepared for 
the FP counseling consultation.
3.2 | Results of alpha testing and revision
To increase readability, wording, sentences and tables were 
changed in the first draft. For example, “FP options” was 
changed into “possibilities to have children in the future,” 
enumerations were used to clarify complex sentences, and 
the text was shortened and detailed information was removed 
from tables to increase readability for patients with a low 
health literacy.
3.2.1 | Alpha testing round 1
Consensus was reached on the adjustments with the steering 
group, and the second draft was ready for evaluation. In total, 
17 out of 24 female cancer survivors and patient advocates 
consented to participate. Their characteristics are shown in 
Table  1. Overall, they were satisfied with the content and 
layout and considered it very helpful in decision making. In 
particular, the cancer-specific information and the tool for 
recognizing personal values were of great value. The infor-
mation was comprehensible, and the images were very illus-
trative. All cancer survivors would have liked to use the DA 
if this would have been available. However, they also had 
suggestions to improve the DA. Regarding the content, they 
suggested to add information about the process of accepting 
that a patient might never have children, to move information 
about alternative family building options from “wait and see” 
to “wish to conceive after surviving cancer,” and to be careful 
in giving any false hope or wrong expectations. To increase 
usability, it was suggested to clarify navigation through the 
DA. Cancer survivors also suggested to personalize the DA 
more by choosing which FP options to read about instead of 
going through all options. Last, to increase readability, they 
suggested to make icon arrays and tables visible at a glance 
and to add colors. This led to major changes in the third draft.
3.2.2 | Alpha testing round 2
The third draft was evaluated with 10 professionals. Their 
characteristics are shown in Table S1. In general, profession-
als were very satisfied with the content, format, and layout 
of the DA. They had fewer suggestions to improve the DA 
than survivors had. They suggested to add a disclaimer to 
emphasize that the information is based on current guide-
lines, but is subject to change over time. In addition, they 
suggested to clarify which treatment (cancer or FP) is meant 
in various places throughout the DA. Specifically for the gy-
necological DAs, it was suggested to alter the images of the 
fertility sparing treatments to make them more clear. Results 
from the questionnaire are shown in Table 2. All profession-
als would recommend the use of the DA and scored it with 
an 8.5 (scale 1–10, SD 0,53). All suggestions were included 
in the fourth draft.
3.2.3 | Alpha testing round 3
The fourth draft was sent to 23 female cancer survivors and 
patient advocates of whom 21 responded (Table 1). Results 
from the questionnaire are shown in Table 2. The DA was 
scored as balanced, clear, comprehensible, and 95% would 
find it useful in decision making. Confusing items were re-
ported by 29%, this concerned word use for which sugges-
tions were made, the usability of the comparison table, and 
clearness of risks. All participants would recommend the 
DA to others and scored the DA with an 8,5 (scale 1–10, SD 
0,75). Based on the improvement suggestions, a final version 
of the DAs was drafted with the project and steering group.
3.2.4 | IPDAS criteria
The checklist of the IPDAS collaboration was used to assess 
the quality of our DA.20 A total of 45 out of 64 criteria on the 
checklist were applicable to our study. Criteria on the field-
testing and effectiveness were not applicable as this has not 
been evaluated yet. The final version of the DA met 43 out 
of the 45 (96%) applicable IPDAS criteria (Table S2). In the 
content domain, all 23 criteria were met. Regarding the de-
velopment process domain, 19 out of 21 criteria were met. 
We did not meet the criteria that the online DA allows pa-
tients to search for key words. Furthermore, the criteria that 
patients received feedback on personal entered information 
were not met, as patients did not have to enter personal infor-
mation because the DA was already cancer-specific.
4 |  DISCUSSION
This paper described the systematic development process of 
24 cancer-specific FP DAs for female cancer patients by a 
multidisciplinary steering group. All DAs addressed risks, 
safety, pros, and cons of “wait and see,” and of all applica-
ble FP treatments. The final versions were considered clear, 
appropriate, usable, and helpful in decision making by fe-
male cancer survivors, patient advocates, and their healthcare 
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T A B L E  1  Characteristics of female cancer survivors and patient advocates in alpha testing round 1 and round 3









Mean age in years (range)
Current 35.3 (23–49) 52.7 (43–69) 34.8 (23–49) 56 (43–70)
At diagnosis 28.6 (19–35) 28.4 (19–35)
Gender (% female) 100% 75% 100% 67%
Education level (N, %)
Secondary education 1/13 (7.7%)
Vocational education 2/13 (15.4%) 1/4 (25%) 3/18 (16.7%) 1/3 (33%)
Higher professional education 5/13 (38.5%) 2/4 (50%) 6/18 (33.3%) 1/3 (33%)
University degree 5/13 (38.5%) 1/4 (25%) 9/18 (50%) 1/3 (33%)
Diagnosis (N, %)
Breast cancer 5/13 (38.5%) 7/18 (38.9%)
Cervical cancer 4/13 (30.8%) 5/18 (27.8%)
Endometrial cancer 1/18 (5.6%)
Hodgkin's disease 2/13 (15.4%) 2/18 (11.1%)
Ovarian cancer 1/13 (7.7%) 1/18 (5.6%)
Soft tissue sarcoma 1/13 (7.7%) 1/18 (5.6%)
Vulvar cancer 1/18 (5.6%)
Advocate of (N, %)
Breast cancer 2/4 (50%) 2/3 (67%)
Hematological malignancy 1/4 (25%) 1/3 (33%)
Gynecological malignancy 1/4 (25%)
Mean years of experience as advocate (range) 7.0 (3–9) 7.7 (5–10)
Cancer treatment (N, %)
Surgery breast 5/13 (38.5%) 7/18 (38.9%)
Surgery reproductive organs 4/13 (30.8%) 7/18 (38.9%)
Chemotherapy 11/13 (84.6%) 14/18 (77.8%)
Radiotherapy (reproductive organs) 3/13 (23.1%) 3/18 (16.7%)
Targeted therapy 1/13 (7.7%) 1/18 (5.6%)
Endocrine therapy 2/13 (15.4%) 2/18 (11.1%)
Relationship status at diagnosis (N, %)
Single 4/13 (30.8%) 5/18 (27.8%)
In a relationship 5/13 (38.5%) 8/18 (44.4%)
Married 4/13 (30.8%) 5/18 (27.8%)
Parity at diagnosis
Nulliparous 10/13 (76.9%) 15/18 (83.3%)
Parous 3/13 (23.1%) 3/18 (16.7%)
Strength of wish to conceive on a scale of 1–10 
(mean, range)
7.1 (2–10)
Fertility discussed (N, %)
Yes 11/13 (84.6%) 15/18 (83.3%)
No 2/13 (15.4%) 3/18 (16.7%)
(Continues)
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professionals. Furthermore, 43 out of 45 quality criteria for 
content and development process of the IPDAS checklist 
were met.
This is the first study in which a FP DA tailored to all can-
cer types and treatment was developed. In previous studies, 
FP DAs have been developed either for one specific cancer 
type or not specific to any cancer type.15 These DAs proved to 
be effective in improving knowledge and reducing decisional 
conflict. The structure of these DAs is the same as ours; how-
ever, tailoring information to a patient's individual situation 
has also shown to be very important in making high-quality 
decisions. In the study of Ehrbar et al, tailored information 
for three specific cancer types (breast cancer, lymphoma, and 
ovarian cancer) was provided, but not for all cancer types.27 
In a narrative review, a wide range of factors was found to 
impact the FP decision-making process, including a patient's 
personal situation, and a patient's dilemma of being in the 
survival mode or to prioritize FP treatment.28 Another quali-
tative study explored breast cancer patients' experiences with 
FP discussions and information.29 Patients reported a strong 
desire to have their individual preferences and personal situ-
ations addressed during fertility discussions, and therefore, 
predetermined FP information would not be appropriate. 
These studies emphasize the need of tailoring information to 
patient's specific values and preferences, which can be done 
by providing our tailored DA.
Noteworthy, our study underlines the importance of involv-
ing patients in all stages during the development of the DA. 
Most studies describing the development of a FP DA also 
involved patients in the development process, however not 
throughout all stages.27,30-32 For example in the study of Jones 
et al., patients were not involved in the first stage, developing 
the first draft.30 Our DA would have been different if patients 
were not involved throughout all stages. To develop the first 
draft of our DA, female cancer survivors were members of our 
steering group, and we explored patients' needs and preferences 
in decision making. This led to the development of DAs that 
were cancer-specific, and provided information about a pa-
tient's personal risk of infertility. If we did not involve them in 
the first stage of development, we would not have developed 24 
cancer-specific DAs. Furthermore, our statements in the value 
clarification exercise were based on patients' values extracted 
from the interviews. In other studies, it was not clear whether 
the statements were based on patients' values.27,30-32 Our exer-
cise was based on the whole process of decision making, that 
is, whether to undergo a FP treatment or not, which is different 
to other DAs.27,31,32 We chose to do it like this, because of two 
reasons. First, this was the main scope of our DA. Second, inter-
viewed patients mentioned that this exercise would help them 
in making the decision whether to undergo a FP treatment or 
not, but not in which FP treatment to choose. They wanted to 
discuss that in more detail with their reproductive gynecologist. 
In the next stages of development, other female cancer survi-
vors were asked to evaluate the DAs where after major changes 
were made to increase the usability and readability of the DA. 
So, although patients were involved in developing the first draft, 









Fertility preservation counseling received (N, 
%)
Yes, by reproductive gynecologist 7/13 (53.8%) 10/18 (55.6%)
Yes, by gynecological oncologist 4/13 (30.8%) 2/18 (11.1%)
No 2/13 (15.4%) 6/18 (33.3%)
Fertility preservation treatment (N, %)
Yes 10/13 (76.9%) 10/18 (55.6%)
Oocyte cryopreservation 3/10 3/10
Embryo cryopreservation 1/10 1/10
Ovarian tissue cryopreservation 2/10 3/10
Ovarian transposition 3/10 3/10
Fertility sparing surgery 3/10 2/10
Hormonal ovarian suppression 1/10 1/10
Combined treatments 3/10 3/10
No 3/13 (23.1%) 8/18 (44.4%)
Pregnancy pursued (N, %) 1/13 (7.7%) 3/18 (16.7%)
Stored material used (N, %) 0 1/18 (5.6%)
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Female cancer survivors and patient 
advocates (n = 21)
Time spent in minutes (range) 30 (20–50) 24 (10–60)
Length
Too long 0 0
Too short 0 0
Just right 10 (100%) 21 (100%)
Amount of information
Too much 0 1 (4.8%)
Too little 0 1 (4.8%)
Just right 9 (90%) 19 (90.4%)
Missing 1 (10%)
Information balanced?
Yes 9 (90%) 21 (100%)
No, leaning toward wait and see 0 0
No, leaning toward fertility preservation 0 0
Missing 1 (10%)
DA comprehensible in general?
Very good 2 (20%) 11 (52.4%)




Very good 5 (50%) 6 (28.5%)
Good 4 (40%) 14 (66.7%)




Very good 4 (40%) 9 (42.9%)
Good 6 (60%) 12 (57.1%)
Moderate 0 0
Bad 0 0
Information appropriate for patients?
Very good 8 (80%) 10 (47.6%)
Good 2 (20%) 8 (38.1%)




Very good 6 (60%) 10 (47.6%)
Good 3 (30%) 9 (42.9%)
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the final versions of the DAs were still considerably different 
underlining the importance to involve patients throughout all 
steps of DA development.
A strength of our study is that it is one of the few studies in 
which three consecutive rounds of alpha testing and revisions 
were conducted to optimize the DA. Our number of participants 
(female cancer survivors N = 38, professionals N = 10) in alpha 
testing was higher than in most studies (female cancer survi-
vors N = 10–20, professionals N = 7–17).27,30-34 This ensured 
we involved female cancer survivors with all types of cancers 
and treatments, of all reproductive ages, and of whom some 
had undergone a FP treatment, while others had not. Our study 
showed that this was of utmost importance in the development 
of the gynecological cancer DAs, as major changes were made 
according to feedback during alpha testing.
Some limitations, despite the systematic development ac-
cording to international standards, should be considered in the 
interpretation of the results. Although we included a high num-
ber of female cancer survivors in alpha testing, the DAs were 
not tested with newly diagnosed cancer patients who might have 
different information and decision support needs. However, an 
advantage of testing with female cancer survivors is that they 
were also aware of the consequences of their decision. This 
provided us with additional information that newly diagnosed 
patients probably could not have overseen. Furthermore, bias 
could have occurred because most female cancer survivors had 
a partner and a strong wish to conceive before decision making. 
Patients who were single and who had doubts about their wish 
to conceive may make their decision based on different informa-
tion and values. In addition, most female cancer survivors were 
highly educated which may bias the results regarding the com-
prehensibility and usability of the DA. However, to minimize 
this bias we involved an organization with experience in adjust-
ing medical texts for low literacy patients. Another limitation of 
our study was that we did not involve partners. Partners may play 
an important role in FP decision making; however, most patients 
indicated that it was their own decision and their partner did not 




Female cancer survivors and patient 
advocates (n = 21)
Credibility?
Very 3 (30%) 13 (61.9%)
Moderate 7 (70%) 8 (38.1%)
A little 0 0
Not at all 0 0
Confusing items?
Yes 4 (40%) 6 (28.5%)
No 6 (60%) 15 (71.5%)
Images helpful?
Very 8 (80%) 15 (71.5%)
Moderate 1 (10%) 6 (28.5%)
A little 0 0
Not at all 0 0
Missing 1 (10%)
Personal value clarification helpful?
Made choice easier 7 (70%) 11 (52.4%)
Made choice harder 0 0
Does not influence choice 2 (20%) 9 (42.9%)
Missing 1 (10%) 1 (4.8%)
DA helpful in decision making?
Very 9 (90%) 12 (57.1%)
Moderate 1 (10%) 8 (38.1%)
A little 0 1 (4.8%)
Not at all 0 0
Average score on scale of 1–10 (range)? 8.5 (8–9) 8.5 (7–10)
Recommend use of DA? (%) 100% 100%
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Caucasian patients, who may make decisions based on other 
cultural values than sexual or racial minorities. Last, although 
the information in the DAs was tailored and cancer-specific, 
it should only be used complementary to FP counseling and 
should not replace counseling. Oncological healthcare providers 
should still refer all patients to a reproductive specialist to dis-
cuss the information in the DA.
The next step in our development process is to field-test 
the DAs in “real life” conditions with patients and profession-
als not involved in the development process.19 This will lead 
to the final version of the DA, which is then ready for imple-
mentation into daily clinical practice. This implementation 
will be facilitated, because multiple key stakeholders, both 
healthcare providers working in oncology care and repro-
ductive medicine, and patient associations, were already in-
volved in the development process.35 Thereafter, it should be 
evaluated if the DA reduces decisional conflict and decision 
regret regarding FP decision making. Our final version of the 
FP DA can be translated and adjusted according to local and 
(inter)national guidelines and available FP options to make it 
broadly available for female cancer patients.
In conclusion, a FP DA tailored to cancer type and associated 
cancer treatments was systematically developed for female can-
cer patients of reproductive age. The DA aims to support patients 
in well-informed FP decision making based on their personal 
situations and preferences. The involvement of healthcare pro-
viders, female cancer survivors, and patient associations led to a 
final version of the DA that is highly appraised, valid, and usable 
in decision making. After field-testing and evaluating the impact 
on decision making in newly diagnosed patients, the DA will be 
available in the Netherlands, and internationally, after translation 
and adjustment to international guidelines and locally available 
FP options.
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